ASCO 2019 Annual Meeting
ASCO 2019 Prostate Cancer
- ASCO 2019: A Multicentric Phase II Randomized Trial of Docetaxel plus Enzalutamide versus Docetaxel as First-line Chemotherapy for Patients with Metastatic Castration-resistant Prostate Cancer: CHEIRON Study
- ASCO 2019: Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy in Men with Clinically Localized, High-Risk Prostate Cancer - CALGB 90203 (Alliance)
- ASCO 2019: Clinical and Safety Outcomes of TALAPRO-2: A Two-part Phase III Study of Talazoparib in Combination with Enzalutamide in Metastatic Castration-resistant Prostate Cancer
- ASCO 2019: Predictive Biomarkers in Prostate Cancer
- ASCO 2019: Abiraterone Acetate plus Prednisone without Continuing LHRH-Therapy in Patients with Metastatic Chemotherapy: Naive Castrations-Resistant Prostate Cancer — Results from the SPARE-Trial
ASCO 2019 Bladder Cancer
- ASCO 2019: Vofatamab in Combination with Pembrolizumab in WT Metastatic Urothelial Carcinoma: FIERCE-22
- ASCO 2019: Targeted Therapeutics and Patient Selection in Advanced Urothelial Carcinoma
- ASCO 2019: Clinical Outcomes According to PD-L1 Status and Age in the Prospective International SAUL Study of Atezolizumab for Locally Advanced or Metastatic Urothelial Carcinoma or Non-UC of the Urinary Tract
- ASCO 2019: Pembrolizumab for Patients with High-Risk Non–Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin: Updated Follow-Up from KEYNOTE-057
- ASCO 2019: Comprehensive Genomic Profiling of Upper-Tract and Bladder Urothelial Carcinoma Reveals Opportunities for Therapeutic and Biomarker Development
ASCO 2019 Kidney Cancer
- ASCO 2019: IMmotion151 Subgroup Analysis: Atezolizumab + Bevacizumab versus Sunitinib in Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Histology
- ASCO 2019: CheckMate 214 Post-Hoc Analyses of Nivolumab plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma with Sarcomatoid Features
- ASCO 2019: Efficacy of Immune Checkpoint Inhibitors and Genomic Characterization of Sarcomatoid and/or Rhabdoid Metastatic Renal Cell Carcinoma
- ASCO 2019: Patient-Reported Outcomes in IMmotion150: Atezolizumab alone or with Bevacizumab versus Sunitinib in First-Line Metastatic Renal Cell Carcinoma
- ASCO 2019: Sarcomatoid RCC: Defining a New Treatment Paradigm?
ASCO 2019 Press Releases
- Janssen Seeks to Expand Use of ERLEADA® (apalutamide) in the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer
- Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer
- ASCO 2019: TITAN: Apalutamide Meets Dual Primary Endpoints, Shows Good Tolerability in Metastatic Hormone Sensitive Prostate Cancer
- ASCO Announces Top Studies to Be Presented at 2019 Annual Meeting
- Myriad Genetics to Present Multiple Studies at the 2019 American Society of Clinical Oncology Annual Meeting
E-Newsletters
Free Daily and Weekly newsletters offered by content of interest
The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.